

# Dose–response effects of exercise training on the subjective sleep quality of postmenopausal women: exploratory analyses of a randomised controlled trial

Christopher E Kline,<sup>1</sup> Xuemei Sui,<sup>2</sup> Martica H Hall,<sup>1</sup> Shawn D Youngstedt,<sup>2,3,4</sup> Steven N Blair,<sup>2,5</sup> Conrad P Earnest,<sup>6</sup> Timothy S Church<sup>7</sup>

**To cite:** Kline CE, Sui X, Hall MH, *et al.* Dose–response effects of exercise training on the subjective sleep quality of postmenopausal women: exploratory analyses of a randomised controlled trial. *BMJ Open* 2012;2:e001044. doi:10.1136/bmjopen-2012-001044

► Prepublication history for this paper are available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2012-001044>).

Received 21 February 2012  
Accepted 18 June 2012

This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see <http://bmjopen.bmj.com>

For numbered affiliations see end of article.

## Correspondence to

Dr Christopher E Kline;  
klinec@upmc.edu

## ABSTRACT

**Objective:** To investigate whether a dose–response relationship existed between exercise and subjective sleep quality in postmenopausal women. This objective represents a post hoc assessment that was not previously considered.

**Design:** Parallel-group randomised controlled trial.

**Setting:** Clinical exercise physiology laboratory in Dallas, Texas.

**Participants:** 437 sedentary overweight/obese postmenopausal women.

**Intervention:** Participants were randomised to one of four treatments, each of 6 months of duration: a non-exercise control treatment (n=92) or one of three dosages of moderate-intensity exercise (50% of VO<sub>2peak</sub>), designed to meet 50% (n=151), 100% (n=99) or 150% (n=95) of the National Institutes of Health Consensus Development Panel physical activity recommendations. Exercise dosages were structured to elicit energy expenditures of 4, 8 or 12 kilocalories per kilogram of body weight per week (KKW), respectively. Analyses were intent to treat.

**Primary outcome measures:** Continuous scores and odds of having significant sleep disturbance, as assessed by the Sleep Problems Index from the 6-item Medical Outcomes Study Sleep Scale. Outcome assessors were blinded to participant randomisation assignment.

**Results:** Change in the Medical Outcomes Study Sleep Problems Index score at 6 months significantly differed by treatment group (control: –2.09 (95% CI –4.58 to 0.40), 4 KKW: –3.93 (–5.87 to –1.99), 8 KKW: –4.06 (–6.45 to –1.67), 12 KKW: –6.22 (–8.68 to –3.77); p=0.04), with a significant dose–response trend observed (p=0.02). Exercise training participants had lower odds of having significant sleep disturbance at postintervention compared with control (4 KKW: OR 0.37 (95% CI 0.19 to 0.73), 8 KKW: 0.36 (0.17 to 0.77), 12 KKW: 0.34 (0.16 to 0.72)). The magnitude of weight loss did not differ between treatment conditions. Improvements in sleep quality were not related to changes in body weight, resting parasympathetic control or cardiorespiratory fitness.

**Conclusion:** Exercise training induced significant improvement in subjective sleep quality in

## ARTICLE SUMMARY

### Article focus

- Sleep disturbance is prevalent in postmenopausal women, with 35%–60% reporting significant sleep problems.
- Effective, safe and easily available treatment options for disturbed sleep in postmenopausal women are lacking.
- There has been equivocal evidence as to whether exercise improves sleep in postmenopausal women, though possible dose–response effects have been noted.

### Key messages

- Exercise resulted in significant improvement in subjective sleep quality in postmenopausal women, with reduced odds of having sleep disturbance at postintervention with even 50% of the recommended dose of exercise for adults.
- The effects of exercise on sleep quality were independent of changes in body weight, resting parasympathetic control or cardiorespiratory fitness.

### Strengths and limitations of this study

- The study constitutes the largest randomised controlled trial on exercise and sleep quality, using a structured dose of exercise and a validated measure of sleep quality.
- Only self-reported sleep was assessed; objective measurement of sleep, with either actigraphy or polysomnography, was not conducted.
- Despite the high prevalence of sleep disturbance in the sample, participants were not selected on the basis of sleep complaints.

postmenopausal women, with even a low dose of exercise resulting in greatly reduced odds of having significant sleep disturbance.

**Trial registration number:** clinicaltrials.gov identifier: NCT00011193.

## INTRODUCTION

Disturbed sleep is a common complaint among women, with increasing prevalence beginning at the menopausal transition. Postmenopausal women are more likely to report sleep problems than premenopausal or perimenopausal women,<sup>1</sup> with 35%–60% of postmenopausal women reporting significant sleep problems.<sup>2</sup> The first-line treatment options for sleep complaints, hypnotic medication and cognitive behavioural therapy have associated concerns about the safety of long-term use or treatment availability, respectively.<sup>3,4</sup> Furthermore, results are conflicting on the effect of hormone replacement therapy (HRT) on sleep quality,<sup>5,6</sup> despite the effectiveness of HRT at reducing other menopausal symptoms.

A non-pharmacological treatment that has been traditionally thought to improve sleep is exercise. In epidemiological research, exercise has frequently been associated with better sleep.<sup>7</sup> However, experimental research has provided less compelling evidence,<sup>8</sup> particularly when regarding postmenopausal women. Of the four randomised trials that have investigated the effect of exercise on sleep quality in this population,<sup>9–12</sup> only one reported a significant improvement in subjective sleep quality following an exercise intervention.<sup>12</sup> However, despite the generally negative findings from these studies involving postmenopausal women, possible dose–response effects of exercise on sleep quality were noted. In one of these studies, women who performed at least 225 min of morning exercise per week had less trouble falling asleep compared with those who exercised <180 min per week in the morning.<sup>9</sup> Likewise, another study reported a positive association between walking frequency and improvements in sleep.<sup>11</sup>

To our knowledge, no research has directly investigated the effects of different doses of exercise on sleep quality. The Dose–Response to Exercise in postmenopausal Women (DREW) trial was conducted to investigate the health effects of 50%, 100% and 150% of the National Institutes of Health (NIH) Consensus Development Panel physical activity recommendations in a group of sedentary postmenopausal women.<sup>13</sup> Results on the primary outcomes of the study, cardiorespiratory fitness and blood pressure, have already been reported.<sup>14</sup> Subjective sleep quality was also assessed in this trial as an exploratory outcome, and the data provided herein give the first systematic examination of whether a dose–response relationship exists between exercise and subjective sleep quality. It was hypothesised that, in comparison to a non-exercise control group, subjective sleep quality would improve with increasing dosage of exercise.

## METHODS

A complete description of the recruitment and screening procedures has been published elsewhere.<sup>13</sup> Briefly, the study was a randomised, controlled, multi-arm, parallel-group trial in which the primary purpose

was to examine whether there were dose–response effects on cardiorespiratory fitness and blood pressure with incrementally increasing doses of energy expenditure.<sup>13,14</sup> The study was approved annually by the Cooper Institute Institutional Review Board, and written informed consent was obtained by all participants prior to study involvement.

## Participants


Participants were recruited from the Dallas, Texas, metropolitan area from April 2001 to June 2005. Of 4545 women screened for eligibility, those who were aged 45–75 years, postmenopausal, sedentary ( $\leq 20$  min of exercise on  $\leq 2$  days/week and  $< 8000$  steps/day, averaged over 1 week), overweight or obese (body mass index (BMI) of 25–43 kg/m<sup>2</sup>) and had normal to mildly elevated resting blood pressure (systolic blood pressure of 120–159 mm Hg and diastolic blood pressure  $\leq 99$  mm Hg) were eligible to participate (figure 1). Exclusion criteria included significant cardiovascular disease, recent hospitalisation for mental illness or significant symptoms of depression (score  $\geq 10$  on the Center for Epidemiologic Studies Depression Scale) or any other health condition that would contraindicate participation in an exercise programme. Overall, 464 women were randomised to treatment, with baseline sleep data available for 437 participants.

## Randomisation and retention

Prior to randomisation, participants completed a 2-week run-in period, in which participants received lifestyle modification instruction over the course of six laboratory visits. The primary purpose of this run-in period was to maximise retention and adherence to the subsequent intervention. Participants were compensated for completing baseline and postintervention assessments, with additional compensation based on intervention adherence.<sup>13</sup>

Allocation of participants to treatment conditions was accomplished using a computer-generated randomisation sequence, determined from randomly permuted blocks of equal length with fixed numbers of treatment allotments to balance treatment enrolments over time. Allocation concealment was achieved by placing treatment assignment letters into sequentially numbered opaque envelopes sealed by the study statistician. At the time of randomisation, envelopes were opened by a staff member not affiliated with the randomisation process.<sup>13</sup>

Participants were randomised to one of four treatment conditions: a non-exercise control group, or one of three exercise groups expending 4, 8 or 12 kilocalories per kilogram of body weight per week (KKW). Energy expenditure levels for the exercise groups were designed to correspond with 50%, 100% and 150% of the NIH Consensus Development Panel physical activity recommendations, respectively.<sup>15</sup>



**Figure 1** Participant screening and study flow. Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline Medical Outcomes Study (MOS) Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI, body mass index; KKW, kilocalories of energy expenditure per kilogram of body weight per week.

**Interventions**

Women assigned to the exercise groups participated in three to four training sessions/week for 6 months, alternating between semirecumbent cycle ergometer and treadmill exercise. Training sessions were conducted in a supervised laboratory setting, and exercise dosage was closely monitored for each session. Training intensity was moderate, set at the heart rate associated with 50% of each woman’s VO<sub>2peak</sub> and continuously monitored by heart rate telemetry. To determine the number of calories that needed to be expended each week, participants were weighed weekly and their weight was multiplied by the exercise dosage.

Exercise dose was gradually increased to minimise injury risk. All exercise training groups expended 4 KKW during the first intervention week, with the 4 KKW group

continuing at that dose for 6 months. The 8 and 12 KKW groups increased their energy expenditure by 1 KKW until they reached their appointed exercise doses.

**Blinding**

Although participants could not be blinded to their treatment, staff were separated into intervention and assessment teams to ensure blinding of all assessment staff to participant randomisation assignment. Participants were consistently reminded to refrain from discussing their randomisation assignments with outcome assessment staff.

**Sleep measure**

Subjective sleep quality was assessed with six items from the Medical Outcomes Study (MOS) Sleep Scale.<sup>16</sup> At

baseline and postintervention, participants were asked to respond based on their sleep during the previous 4 weeks. One question, which addressed the length of time to fall asleep, was framed with five response options ranging from 0 to 15 min to >60 min. For the remaining five questions (ie, restless sleep, daytime drowsiness, difficulty falling asleep, awakening from sleep and experiencing difficulty returning to sleep, staying awake during the day), participants were asked to respond on a 5-point scale, ranging from 'none of the time' to 'all of the time'. Item responses were assigned scores using conventional scoring rules, with higher scores indicating a greater severity of sleep disturbance. A modified Sleep Problems Index (SPI), using all six sleep items, provided a measure of overall sleep quality.<sup>17</sup> SPI scores >25 were considered to indicate significant sleep disturbance, as prior work using a 9-item SPI reported that a cutpoint of >25 identified individuals who considered themselves to have a sleep problem with a sensitivity of 86.2% and specificity of 66.3%.<sup>17</sup>

Scores on the MOS Sleep Scale have been shown to correlate with other MOS health items,<sup>16</sup> differentiate between those with and without chronic health conditions<sup>17</sup> and improve with treatment of chronic health conditions.<sup>18</sup> Normative values for the general population have also been developed.<sup>17</sup>

### Other measures

Baseline demographic and health characteristics were assessed by completion of a comprehensive medical history questionnaire. Height and weight were measured with a calibrated stadiometer and electronic scale, respectively. Diet was assessed before and following the intervention using a semiquantitative food-frequency questionnaire, whereas unsupervised physical activity was monitored throughout the study with a pedometer (Accusplit Eagle, Livermore, California).

Cardiorespiratory fitness ( $VO_{2peak}$ ) was assessed from maximal exercise testing using a cycle ergometer (Excalibur Sport, Lode Medical Technology, Groningen, the Netherlands), as previously described.<sup>14</sup> Testing was performed twice at baseline and twice at postintervention, with values from each timepoint averaged. Heart rate variability (HRV) was measured from the final 5 min of a 25-min resting assessment, as previously described.<sup>19</sup> The square root of the mean of the sum of the squares of differences between adjacent R–R intervals (rMSSD), a marker of parasympathetic activity,<sup>20</sup> was retained for analysis.

### Statistical power

Sample size was originally based on having adequate power to detect changes in the primary outcomes of the overall study,  $VO_{2peak}$  and blood pressure.<sup>14</sup> Additional participants were allocated to the 4 KKW condition to increase statistical power for detecting smaller anticipated fitness gains in this group. Because sleep was not a primary outcome in the design of the original study,

there was no opportunity before data collection to investigate sample size or power for this outcome variable. Nevertheless, given the current enrolment, the study had 84% power (assuming two-tailed  $\alpha=0.05$ ) to detect an effect size of 0.20 for MOS SPI score reduction.

### Statistical analysis

Baseline sleep quality was compared against normative data<sup>17</sup> using a one-sample t-test. Continuous MOS SPI values were examined across quartiles of BMI, parasympathetic tone (rMSSD) and cardiorespiratory fitness ( $VO_{2peak}$ ) with analysis of covariance (ANCOVA), controlling for age, BMI, sleep medication use and HRT use. The likelihood of having significant sleep disturbance at baseline (ie, MOS SPI >25) was evaluated with logistic regression across the same quartiles using the same covariates.

Two primary outcomes were evaluated for the current study: (1) change in continuous MOS SPI score across treatment groups and (2) odds of having significant sleep disturbance at postintervention across treatment groups. Change in continuous MOS SPI scores across groups was tested by ANCOVA, with adjustment for age, BMI, sleep medication use, HRT use and baseline MOS SPI values. All assumptions underlying the ANCOVA models were checked and verified to be met. Individual treatment groups were compared with the control group with Tukey–Kramer adjustment for multiple comparisons. An  $\alpha$  level of 0.05 was used because it was our a priori intention to compare only the separate treatment groups with the control group. Dose–response trends were analysed using least-squares regression of MOS SPI change across groups. Logistic regression examined the odds of having significant sleep disturbance at postintervention, following adjustment for age, BMI, sleep medication and HRT use, and baseline sleep disturbance (SPI >25, SPI  $\leq$ 25). Unadjusted analyses provided similar results to those with covariate control, so only those results with full covariate adjustment were reported.

Finally, to examine whether improved sleep quality was significantly influenced by body weight, parasympathetic tone or cardiorespiratory fitness, changes in weight, rMSSD and  $VO_{2peak}$  were added to the ANCOVA and logistic regression analyses. Additionally, among completed participants, changes in MOS SPI score were evaluated across quartiles of change in body weight, rMSSD and  $VO_{2peak}$  following adjustment for age, treatment, BMI, sleep medication use, HRT use and baseline MOS SPI score.

Analyses were limited to participants with baseline MOS Sleep data. Primary analyses were conducted using the intent-to-treat principle; if postintervention data were missing, baseline values were carried forward for analysis. When analyses were restricted to only those participants with baseline and postintervention MOS Sleep data ( $n=359$ ), results were not substantively changed; similarly, when missing postintervention data

were imputed with mean values, results were unchanged. Therefore, only intent-to-treat analyses were presented. All analyses were performed using SAS V.9.2 (SAS Institute). All tests were two-tailed, with statistical significance set at  $p \leq 0.05$ .

## RESULTS

### Participant characteristics

A summary of participant characteristics is provided in table 1. Mean age and BMI of the 437 participants were  $57.3 \pm 6.5$  years and  $31.8 \pm 3.9$  kg/m<sup>2</sup>, respectively.

Baseline MOS SPI values and prevalence of sleep disturbance are provided in table 1. Of the 437 participants, 46% of the sample (n=200) were considered to have significant sleep disturbance at baseline, as defined as MOS SPI >25. Baseline sleep quality of the participants was significantly worse than normative values<sup>17</sup> (normative value: 25.79;  $t_{436}=2.42$ ,  $p=0.02$ ), a magnitude of 0.12 SD.<sup>21</sup>

Baseline continuous MOS SPI values and odds of sleep disturbance across quartiles of BMI, rMSSD and VO<sub>2peak</sub> are shown in table 2. Sleep quality significantly differed

among quartiles of rMSSD ( $F_{3,343}=2.55$ ,  $p=0.05$ ), with the lowest quartile of rMSSD having significantly worse baseline sleep quality than the other quartiles of rMSSD. Similarly, each quartile of rMSSD was associated with lower odds of having significant sleep disturbance at baseline compared with the lowest quartile of rMSSD. No differences in MOS SPI values or odds of having significant sleep disturbance were observed across quartiles of BMI or VO<sub>2peak</sub>.

### Exercise training adherence, diet and unsupervised activity

Treatment adherence was calculated as the percentage of exercise energy expenditure achieved compared with the amount of exercise energy expenditure that was prescribed. Adherence was similar between exercise groups (4 KKW:  $95.1 \pm 16.1\%$ , eight KKW:  $88.5 \pm 26.1\%$ , 12 KKW:  $92.5 \pm 20.9\%$ ), as previously reported.<sup>14</sup>

Changes in diet and unsupervised activity have been previously reported.<sup>14 22</sup> Preintervention to post-intervention changes in energy intake did not differ between treatment conditions. Pedometer-assessed unsupervised activity ranged from 4766 to 5067 steps/

**Table 1** Baseline participant characteristics

	All (N=437)	Control (n=92)	Exercise groups		
			4 KKW (n=151)	8 KKW (n=99)	12 KKW (n=95)
Age, years	57.32 (6.46)	57.14 (5.91)	57.78 (6.53)	57.58 (6.63)	56.47 (6.72)
Education, years	14.03 (2.11)	14.01 (2.12)	13.80 (2.02)	14.37 (2.06)	14.00 (2.28)
Married, n (%)	398 (91)	86 (93)	141 (94)	87 (88)	84 (88)
Ethnicity/race, n (%)					
White	278 (64)	58 (63)	92 (61)	60 (61)	68 (72)
African-American	128 (29)	23 (25)	49 (32)	32 (32)	24 (25)
Hispanic/other	31 (7)	11 (12)	10 (7)	7 (7)	3 (3)
Employed, n (%)	304 (70)	62 (67)	105 (70)	67 (68)	70 (74)
Cigarette smoking, n (%)	25 (6)	5 (5)	8 (5)	4 (4)	8 (8)
Medication use, n (%)					
Antihypertensive	126 (29)	22 (24)	41 (27)	32 (32)	31 (33)
Hyperlipidaemia	73 (17)	14 (15)	31 (21)	17 (17)	11 (12)
Thyroid	65 (15)	12 (13)	19 (13)	16 (16)	18 (19)
Antidepressant	78 (18)	16 (17)	28 (19)	18 (18)	16 (17)
Hormone replacement therapy	202 (46)	48 (52)	67 (44)	43 (43)	44 (46)
Antianxiety	20 (5)	7 (8)	7 (5)	4 (4)	2 (2)
Sedatives/sleep aids	12 (3)	4 (4)	5 (3)	3 (3)	0 (0)
Energy intake, kcal/day	2277.2 (952.6)	2277.4 (947.9)	2213.1 (941.6)	2290.7 (930.7)	2364.7 (1003.5)
Anthropometrics					
Weight, kg	84.46 (11.82)	85.77 (12.43)	83.56 (11.42)	84.74 (12.43)	84.33 (11.24)
Body mass index, kg/m <sup>2</sup>	31.77 (3.85)	32.29 (3.94)	31.54 (3.80)	31.98 (4.08)	31.44 (3.58)
Cardiorespiratory fitness					
Relative VO <sub>2peak</sub> , ml/kg/min	15.37 (2.92)	15.56 (3.00)	15.44 (3.00)	14.70 (2.49)	15.77 (3.05)
Absolute VO <sub>2peak</sub> , l/min	1.29 (0.26)	1.33 (0.28)	1.28 (0.24)	1.24 (0.24)	1.32 (0.26)
Heart Rate Variability*					
rMSSD, ms	22.83 (11.56)	23.35 (11.01)	23.58 (12.24)	23.25 (11.29)	20.68 (11.19)
Subjective sleep quality					
MOS Sleep Problems Index	27.92 (18.40)	28.37 (19.71)	27.03 (17.92)	27.35 (18.10)	29.47 (18.32)
Sleep disturbance, n (%)	200 (46)	38 (41)	65 (43)	49 (49)	48 (51)

Data presented as mean (SD) unless otherwise indicated.

\*Samples for rMSSD data were 351, 79, 123, 73 and 76 participants for all, control, 4 KKW, 8 KKW and 12 KKW groups, respectively. KKW, kilocalories of energy expenditure per kilogram of body weight per week; MOS, Medical Outcomes Study; rMSSD, square root of the mean of the sum of the squares of differences between adjacent R-R intervals; VO<sub>2peak</sub>, peak rate of oxygen consumption.

**Table 2** Associations between baseline sleep quality and BMI, parasympathetic tone and cardiorespiratory fitness

Variable	MOS SPI score (95% CI)	OR of MOS SPI >25 (95% CI)
<b>BMI (kg/m<sup>2</sup>)</b>		
Q1: ≥34.7	27.95 (24.54 to 31.36)	1.00 (Referent)
Q2: 31.7 to <34.7	24.37 (20.92 to 27.82)	0.60 (0.35 to 1.03)
Q3: 28.6 to <31.7	30.48 (27.03 to 33.94)	1.14 (0.67 to 1.96)
Q4: <28.6	28.85 (25.46 to 32.24)	0.98 (0.58 to 1.68)
Linear p	0.26	0.53
<b>rMSSD (ms)</b>		
Q1: <15.0	31.77 (27.95 to 35.59)	1.00 (Referent)
Q2: 15.0 to <20.9	24.77 (21.04 to 28.51)*	0.53 (0.29 to 0.97)
Q3: 20.9 to <29.0	25.22 (21.36 to 29.09)*	0.43 (0.23 to 0.81)
Q4: ≥29.0	26.50 (22.64 to 30.35)*	0.46 (0.25 to 0.86)
Linear p	0.08	0.01
<b>VO<sub>2peak</sub> (ml/kg/min)</b>		
Q1: <13.4	29.55 (25.86 to 33.25)	1.00 (Referent)
Q2: 13.4 to <15.2	28.80 (25.35 to 32.25)	1.22 (0.70 to 2.13)
Q3: 15.2 to <17.0	28.60 (25.05 to 32.15)	1.04 (0.58 to 1.87)
Q4: ≥17.0	24.91 (21.41 to 28.42)	0.63 (0.34 to 1.14)
Linear p	0.10	0.09

Continuous baseline MOS SPI scores (left panels) and ORs of having significant sleep disturbance at baseline (MOS SPI >25) (right panels) across quartiles of baseline BMI, rMSSD and VO<sub>2peak</sub>. All analyses adjusted for age, BMI, sleep medication use and HRT use, except when the covariate quartile was the independent variable.

\*Significant difference (p≤0.05) in MOS SPI score compared with quartile 1 (referent group).

BMI, body mass index; MOS, Medical Outcomes Study; Q, quartile; rMSSD, square root of the mean of the sum of the squares of differences between adjacent R–R intervals; SPI, Sleep Problems Index; VO<sub>2peak</sub>, peak rate of oxygen consumption.

day at baseline and did not differ between groups. Compared with baseline, daily steps increased for each group at month 1 (each p<0.05), with greater steps in the control group than the three exercise groups (each p<0.05). However, no differences in daily steps between the control and exercise groups were observed by months 5 and 6. Among the exercise groups, daily steps did not change from months 1 through 6. Therefore, the results reported here are unlikely to be due to changes in diet or spontaneous activity outside the exercise training laboratory.


### Changes in sleep quality with exercise training

Changes in sleep quality with exercise training are depicted in figure 2. A significant effect of the intervention was noted in the full model (F<sub>8,428</sub>=17.35, p<0.001), with treatment group being an independent predictor of change in continuous MOS SPI score (F<sub>3,428</sub>=2.79, p=0.04) following control for age, BMI, HRT use, sleep medication use and baseline MOS SPI values. Moreover, a significant linear dose–response effect was found for MOS SPI scores across treatment groups (p=0.02). When compared against control, a significantly greater improvement in MOS SPI score was found for the 12 KKW group (p=0.02).

The association between sleep disturbance (ie, MOS SPI >25) at postintervention and treatment is summarised in table 3. Compared with control and following covariate adjustment, each exercise training group had lower odds of having significant sleep disturbance following the intervention, with the odds of having significant sleep disturbance decreasing while exercise dose increased (linear trend p=0.01).

### Influences of change in weight, fitness and parasympathetic tone on sleep

Postintervention changes in body weight, parasympathetic tone and cardiorespiratory fitness for the overall DREW sample have been previously reported.<sup>14 19</sup> In the present study's sample, the magnitude of weight loss did not differ between treatment groups (control: -1.08 (3.70), 4 KKW: -1.23 (3.43), 8 KKW: -1.60 (3.23), 12 KKW: -1.25 (2.83) kg; F<sub>3,433</sub>=0.43, p=0.73). Cardiorespiratory fitness improved with exercise training in a dose–dependent manner (control: -0.20 (1.88),



**Figure 2** Change in Medical Outcomes Study (MOS) Sleep Problems Index (SPI) scores among treatment groups. Data presented as least-squares means±95% CIs. Analyses adjusted for age, body mass index, sleep medication use, hormone replacement therapy use and baseline MOS SPI score. Asterisk indicates difference from control (p=0.02). KKW, kilocalories of energy expenditure per kilogram of body weight per week.

**Table 3** Prevalence and odds of significant sleep disturbance (ie, Medical Outcomes Study SPI >25) at postintervention

	Prevalence n (%)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Model 3 OR (95% CI)	Model 4 OR (95% CI)
Control	41 (45)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)	1.00 (Referent)
4 KKW	46 (31)	0.37 (0.19 to 0.73)	0.37 (0.19 to 0.73)	0.34 (0.19 to 0.73)	0.37 (0.19 to 0.73)
8 KKW	33 (33)	0.36 (0.17 to 0.77)	0.36 (0.17 to 0.77)	0.32 (0.17 to 0.77)	0.36 (0.17 to 0.77)
12 KKW	31 (33)	0.34 (0.16 to 0.72)	0.34 (0.16 to 0.72)	0.28 (0.16 to 0.72)	0.34 (0.16 to 0.72)
Linear trend P		0.01	0.01	0.006	0.02
Weight change		—	1.00 (0.93 to 1.08)	—	—
VO <sub>2peak</sub> change		—	—	1.10 (0.95 to 1.26)	—
rMSSD change		—	—	—	1.01 (0.98 to 1.04)

Model 1 adjusted for age, BMI, sleep medication use, hormone replacement therapy use and baseline sleep quality (SPI ≤25, SPI >25); model 2 adjusted for change in body weight in addition to variables included in model 1; model 3 adjusted for change in VO<sub>2peak</sub> in addition to variables included in model 1; model 4 adjusted for change in rMSSD in addition to variables included in model 1.

KKW, kilocalories of energy expenditure per kilogram of body weight per week; rMSSD, square root of the mean of the sum of the squares of differences between adjacent R–R intervals; SPI, Sleep Problems Index; VO<sub>2peak</sub>, peak rate of oxygen consumption.

4 KKW: 0.59 (1.83), 8 KKW: 1.13 (1.54), 12 KKW: 1.42 (1.79) ml/kg/min;  $F_{3,433}=15.32$ ,  $p<0.001$ ). Among those with usable HRV and sleep data ( $n=351$ ), rMSSD improved in a dose–dependent fashion with exercise training (control: 0.20 (8.45), 4 KKW: 2.72 (9.20), 8 KKW: 3.72 (11.47), 12 KKW: 5.29 (9.51) ms;  $F_{3,347}=3.82$ ,  $p=0.01$ ). When added to the model analysing differences in continuous MOS SPI change among treatment groups, none of these covariates were significant ( $p\leq 0.14$ ), and inclusion of these variables did not alter the previously noted treatment group differences or linear dose–response effects. When individually added to logistic regression analyses, none of these covariates significantly affected the odds of having significant sleep disturbance at postintervention (table 3). In addition, when change in MOS SPI was evaluated across quartiles of change in body weight, rMSSD or VO<sub>2peak</sub>, no significant between-group differences were noted (data not shown). Finally, change in MOS SPI did not correlate with change in body weight, rMSSD or VO<sub>2peak</sub> ( $r<0.03$ ,  $p>0.58$ ).

## DISCUSSION

The key finding from exploratory analyses of the DREW randomised controlled trial was that exercise training significantly improved subjective sleep quality in overweight/obese postmenopausal women. Specifically, we observed a dose–response trend for the continuous MOS SPI values and, perhaps most notably, significantly reduced odds of having sleep disturbance at postintervention with even 50% of the recommended dose of exercise for adults. Interestingly, the improvements in sleep quality were not related to changes in body weight, parasympathetic tone or cardiorespiratory fitness.

### Previous research

Previous research with postmenopausal women had yielded conflicting findings regarding whether exercise improved sleep.<sup>9–12</sup> While suggested by prior studies in this population,<sup>9–11</sup> the present study is the first to document a dose–response relationship between exer-

cise and improved subjective sleep quality. Although sleep was an exploratory outcome of the DREW study, it is the largest clinical trial to date that has examined the relationship between aerobic exercise dose and sleep quality. Our current findings mirror the overall body of research indicating that exercise improves sleep, most prominently in those with existing sleep disturbances.<sup>8</sup>

### Clinical implications

When considering the improvements in continuous MOS SPI scores following exercise training, the clinical significance is uncertain. The observation that only those who exercised at a 12-KKW dose experienced a significant improvement in sleep quality compared with control may be viewed as discouraging, as this dose equated to approximately 190 min/week of moderate-intensity aerobic exercise<sup>14</sup> and many individuals may not be willing to perform that much exercise to improve sleep. However, the significant dose–response effect suggests that any dose of exercise should benefit sleep, albeit with larger effects noted with higher levels of energy expenditure.

In contrast, the greatly reduced odds of having significant sleep disturbance following exercise training suggests that exercise may hold the most promise as a treatment option for postmenopausal women with significant sleep disturbance. In particular, even an exercise dose consisting of 50% of the NIH Consensus Panel physical activity recommendations significantly reduced the odds of having a postintervention MOS SPI >25. This is noteworthy since sleep complaints are prevalent in postmenopausal women,<sup>1</sup> and current treatment options, such as HRT and hypnotic medication, have often been found to be only mildly efficacious at improving sleep quality compared with placebo in postmenopausal women.<sup>6–23</sup>

The mechanisms by which exercise may improve subjective sleep quality in postmenopausal women are unknown. Although the present study was not specifically designed to address mechanisms of effect, secondary analyses focused on changes in three variables

which have been shown to be related to sleep: body weight, parasympathetic activity and cardiorespiratory fitness. There is a clear association between obesity and disturbed sleep,<sup>24</sup> and weight loss has been found to reduce sleep complaints.<sup>25</sup> Likewise, poor sleepers have been found to have impaired sleep HRV,<sup>26</sup> and exercise training has been well documented to improve autonomic function.<sup>27</sup> Finally, physical fitness has been previously associated with sleep quality,<sup>28</sup> and greater improvements in fitness have been associated with better sleep outcomes in some experimental studies.<sup>9–12</sup>

Nonetheless, in the present study, changes in body weight, parasympathetic tone or cardiorespiratory fitness were not significantly related to changes in sleep, whether assessed by covariate control, change in sleep quality across quartiles of change in these variables or correlations between change in these variables and change in sleep quality. Although significant improvements were noted for rMSSD and  $VO_{2peak}$  following exercise training in this sample,<sup>14–19</sup> the variability associated with the sleep measure used in the current study may have masked any possible associations. The present study suggests that exercise training can result in improved sleep quality independent of weight loss, increased fitness or improved autonomic balance.

### Strengths and weaknesses

Strengths of the study include a randomised controlled design, closely supervised intervention, use of a validated measure of sleep quality and the largest experimental sample size to investigate the effects of exercise on sleep. The study population was another strength, as the prevalence of disturbed sleep was high. Finally, assessment of variables that are related to sleep quality and may contribute to improved sleep following exercise training was another strength of the study.

A limitation of the study is that sleep quality was not a primary outcome of the original DREW trial. Therefore, results should be interpreted cautiously. Another study limitation is that sleep was not objectively assessed (ie, via wrist actigraphy or polysomnography). Because of the subjective nature of the outcome and impossibility of blinding participants to their treatment, improvements in self-reported sleep quality may have been subject to expectancy effects, as exercise is commonly believed to improve sleep quality.<sup>7</sup> However, the finding of a significant linear trend between exercise dose and improvement in sleep quality would not necessarily be expected. Moreover, that sleep was not a primary outcome of interest and part of a wide range of study assessments further reduces the chance of expectancy or demand biases. Additionally, there is growing recognition of the merit of assessing subjective sleep quality.<sup>29</sup> For instance, in contrast with subjective sleep quality, objective sleep has not been found to be altered across the menopausal transition.<sup>30</sup> Furthermore, impaired subjective sleep quality is what prompts search for treatment, and recent evidence suggests that traditional objective sleep

measures might be inadequate for detecting subtle indicators of disturbed sleep.<sup>31</sup> It is also noteworthy that subjective sleep quality has been associated with quality of life and physical and mental health in postmenopausal women.<sup>32</sup>

A lack of assessment of obstructive sleep apnoea (OSA) was another limitation. Although OSA is considered to be a male-dominated sleep disorder, postmenopausal OSA prevalence is similar between men and women.<sup>33</sup> Moreover, excess weight is the primary cause of OSA for most adults,<sup>34</sup> which would place this overweight/obese sample at even higher risk for OSA. Evidence suggests that exercise, in the absence of more established treatments or significant weight loss, is moderately efficacious at reducing OSA severity and improving sleep.<sup>35</sup> However, dose–response effects of exercise on OSA severity are unknown.

Finally, because aerobic activity was the only mode of exercise studied in the DREW trial, the possible effects of resistance exercise on sleep quality could not be examined in this sample. Resistance training has been shown to improve sleep quality,<sup>36</sup> though there has been minimal work comparing different doses of resistance exercise on sleep quality.<sup>37</sup>

### Conclusions

In summary, in a sample of overweight/obese postmenopausal women, exercise training significantly reduced the odds of having significant sleep disturbance. These improvements in sleep were independent of the effects of exercise training on body weight, parasympathetic tone or cardiorespiratory fitness. Additional research with more comprehensive measurement of sleep is warranted, but exercise training appears to significantly improve sleep quality in postmenopausal women.

### Author affiliations

<sup>1</sup>Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

<sup>2</sup>Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA

<sup>3</sup>WJB Dorn VA Medical Center, Columbia, South Carolina, USA

<sup>4</sup>Department of Psychology, University of South Carolina, Columbia, South Carolina, USA

<sup>5</sup>Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA

<sup>6</sup>Department for Health, University of Bath, Bath, UK

<sup>7</sup>Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA

**Acknowledgements** We thank the DREW participants and the Cooper Institute staff for their efforts on this study.

**Contributors** TSC and SNB designed and organised the study. TSC, CPE and SNB collected the data. CEK and XS performed the statistical analyses. CEK wrote the first draft of the manuscript. XS, MHH, SDY, CPE, SNB and TSC provided critical input at all stages and critically reviewed and contributed to the final draft. CEK and TSC are guarantors.

**Funding** This work was supported by grants HL66262 and HL082610 from the National Heart, Lung and Blood Institute of the National Institutes of Health, and the American Heart Association Texas Affiliate award 02651404. Life Fitness (Schiller Park, Illinois) provided exercise equipment for this study. The sponsors had no role in the study design, protocol development or in

conducting the trial, data collection, data analysis or preparation of the manuscript.

**Competing interests** None.

**Ethics approval** This study was approved by Institutional Review Boards of the Cooper Institute (Dallas, Texas) and the Pennington Biomedical Research Center (Baton Rouge, Louisiana).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The data set will be available from the corresponding author as part of an academic collaboration.

## REFERENCES

- Kravitz HM, Ganz PA, Bromberger J, *et al*. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause* 2003;10:19–28.
- National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. *Ann Intern Med* 2005;142:1003–13.
- Buscemi N, Vandermeer B, Friesen C, *et al*. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335–50.
- Nowakowski S, Meliska CJ, Martinez LF, *et al*. Sleep and menopause. *Curr Neurol Neurosci Rep* 2009;9:165–72.
- Sarti CD, Chiantera A, Graziottin A, *et al*. Hormone therapy and sleep quality in women around menopause. *Menopause* 2005;12:545–51.
- Kalleinen N, Polo O, Himanen SL, *et al*. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. *Climacteric* 2008;11:233–43.
- Youngstedt SD, Kline CE. Epidemiology of exercise and sleep. *Sleep Biol Rhythms* 2006;4:215–21.
- Youngstedt SD. Effects of exercise on sleep. *Clin Sports Med* 2005;24:355–65.
- Twoogor SS, Yasui Y, Vitiello MV, *et al*. Effects of a yearlong moderate-intensity exercise and a stretching intervention on sleep quality in postmenopausal women. *Sleep* 2003;26:830–6.
- Elavsky S, McAuley E. Lack of perceived sleep improvement after 4-month structured exercise programs. *Menopause* 2007;14:535–40.
- Wilbur J, Miller AM, McDevitt J, *et al*. Menopausal status, moderate-intensity walking, and symptoms in midlife women. *Res Theory Nurs Pract* 2005;19:163–80.
- King AC, Oman RF, Brassington GS, *et al*. Moderate-intensity exercise and self-rated quality of sleep in older adults. A randomized controlled trial. *JAMA* 1997;277:32–7.
- Morss GM, Jordan AN, Skinner JS, *et al*. Dose response to exercise in women aged 45–75 yr (DREW): design and rationale. *Med Sci Sports Exerc* 2004;36:336–44.
- Church TS, Earnest CP, Skinner JS, *et al*. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. *JAMA* 2007;297:2081–91.
- NIH Consensus development panel on physical activity and cardiovascular health. Physical activity and cardiovascular health. *JAMA* 1996;276:241–6.
- Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. *Measuring Functioning and Well-being: The Medical Outcomes Study Approach*. Durham, NC: Duke University Press 1992:235–59.
- Hays RD, Martin SA, Sesti AM, *et al*. Psychometric properties of the medical outcomes study sleep measure. *Sleep Med* 2005;6:41–4.
- Allen RP, Kosinski M, Hill-Zabala CE, *et al*. Psychometric evaluation and tests of validity of the medical outcomes study 12-item sleep scale (MOS sleep). *Sleep Med* 2009;10:531–9.
- Earnest CP, Lavie CJ, Blair SN, *et al*. Heart rate variability characteristics in sedentary postmenopausal women following six months of exercise training: the DREW study. *PLoS One* 2008;3:e2288.
- Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. *Eur Heart J* 1996;17:354–81.
- Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd edn. Philadelphia, PA: Lawrence Erlbaum Associates, Inc, 1988.
- Church TS, Martin CK, Thompson AM, *et al*. Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women. *PLoS One* 2009;4:e4515.
- Soares CN, Joffe H, Rubens R, *et al*. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. *Obstet Gynecol* 2006;108:1402–10.
- Fogelholm M, Kronholm E, Kukkonen-Harjula K, *et al*. Sleep-related disturbances and physical inactivity are independently associated with obesity in adults. *Int J Obes (Lond)* 2007;31:1713–21.
- Dixon JB, Schachter LM, O'Brien PE. Sleep disturbance and obesity: changes following surgically induced weight loss. *Arch Intern Med* 2001;161:102–6.
- Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. *Psychosom Med* 1998;60:610–15.
- Routledge FS, Campbell TS, Fetridge-Durdle JA, *et al*. Improvements in heart rate variability with exercise therapy. *Can J Cardiol* 2010;26:303–12.
- Lee AJ, Lin WH. Association between sleep quality and physical fitness in female young adults. *J Sports Med Phys Fitness* 2007;47:462–7.
- Buysse DJ, Reynolds CF III, Monk TH, *et al*. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193–213.
- Young T, Rabago D, Zgierska A, *et al*. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. *Sleep* 2003;26:667–72.
- Perlis ML, Smith MT, Andrews PJ, *et al*. Beta/gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. *Sleep* 2001;24:110–17.
- Baker FC, Wolfson AR, Lee KA. Association of sociodemographic, lifestyle, and health factors with sleep quality and daytime sleepiness in women: findings from the 2007 National Sleep Foundation "Sleep in America Poll". *J Womens Health* 2009;18:841–9.
- Young T, Finn L, Austin D, *et al*. Menopausal status and sleep-disordered breathing in the Wisconsin sleep Cohort study. *Am J Respir Crit Care Med* 2003;167:1181–5.
- Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol* 2005;99:1592–9.
- Kline CE, Crowley EP, Ewing GB, *et al*. The effect of exercise training on obstructive sleep apnea and sleep quality: a randomized controlled trial. *Sleep* 2011;34:1631–40.
- Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of exercise on sleep. *Sleep* 1997;20:95–101.
- Singh NA, Stavrinou TM, Scarbek Y, *et al*. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *J Gerontol A Biol Sci Med Sci* 2005;60:768–76.



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	p.1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	pp. 2-3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	pp. 5-6
	2b	Specific objectives or hypotheses	p. 6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	p. 6, p. 10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	pp. 6-7
	4b	Settings and locations where the data were collected	p. 6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	pp. 7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	pp. 8-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	p. 10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	p. 7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	p. 7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	p. 7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	p. 7

Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	p. 8
	11b	If relevant, description of the similarity of interventions	p. 7
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	pp. 10-11
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	pp. 10-11
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	p. 12; Fig. 1
	13b	For each group, losses and exclusions after randomisation, together with reasons	Fig. 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	p. 6
	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	p. 12, Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	p.11, Fig. 1
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	p. 13, Fig. 2, Table 3
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	p. 13, Table 3
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	pp. 13-14
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	pp. 16-18
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	p. 15, pp. 17-18
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	pp. 14-15
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	p. 3, p. 20
Protocol	24	Where the full trial protocol can be accessed, if available	p. 6, Ref. 13
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	pp. 19-20

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).